Back to School: How biopharma can reboot drug development. Access exclusive analysis here

FDA revises ESA labels

FDA and Amgen (AMGN) on Thursday released new labels for erythropoiesis-stimulating agents (ESAs). The label recommends discontinuing ESA administration for any indication

Read the full 222 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE